| Literature DB >> 28329184 |
Anna Bershetyn1, Thomas A Odeny2, Rita Lyamuya3, Alice Nakiwogga-Muwanga4, Lameck Diero5, Mwebesa Bwana6,7, Paula Braitstein5, Geoffrey Somi3, Andrew Kambugu4, Elizabeth Bukusi2, Wendy Hartogensis8, David V Glidden6, Kara Wools-Kaloustian9, Constantin Yiannoutsos10, Jeffrey Martin6,8, Elvin H Geng8.
Abstract
BACKGROUND.: The effect of tracing human immunodeficiency virus (HIV)-infected patients who are lost to follow-up (LTFU) on reengagement has not been rigorously assessed. We carried out an ex post analysis of a surveillance study in which LTFU patients were randomly selected for tracing to identify the effect of tracing on reengagement. METHODS.: We evaluated HIV-infected adults on antiretroviral therapy who were LTFU (>90 days late for last visit) at 14 clinics in Uganda, Kenya, and Tanzania. A random sample of LTFU patients was selected for tracing by peer health workers. We assessed the effect of selection for tracing using Kaplan-Meier estimates of reengagement among all patients as well as the subset of LTFU patients who were alive, contacted in person by the tracer, and out of care. RESULTS.: Of 5781 eligible patients, 991 (17%) were randomly selected for tracing. One year after selection for tracing, 13.3% (95% confidence interval [CI], 11.1%-15.3%) of those selected for tracing returned compared with 10.0% (95% CI, 9.1%-10.8%) of those not randomly selected, an adjusted risk difference of 3.0% (95% CI, .7%-5.3%). Among patients found to be alive, personally contacted, and out of care, tracing increased the absolute probability of return at 1 year by 22% (95% CI, 7.1%-36.2%). The effect of tracing on rate of return to clinic decayed with a half-life of 7.0 days after tracing (95% CI, 2.6 %-12.9%). CONCLUSIONS.: Tracing interventions increase reengagement, but developing methods for targeting LTFU patients most likely to benefit can make this practice more efficient.Entities:
Keywords: Africa; antiretroviral therapy; loss to follow-up.; retention
Mesh:
Substances:
Year: 2017 PMID: 28329184 PMCID: PMC5848300 DOI: 10.1093/cid/cix191
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 20.999